All
Researchers identify 'triangle sign' as key diagnostic marker in ocular pathologies
The “Triangle sign” seen on ultrasound is a “distinctive and reliable” ultrasound feature for differentiating total choroidal detachments and suprachoroidal hemorrhages.
10-year data shows progressive visual decline in myopic children and adults
Effects of premature birth on the retina of adults
The investigators found that the premature births to be associated with vascular changes on ocular coherence tomography-angiography.
NeurEYE team leads AI research to detect dementia through retinal imaging
The NeurEYE research team will use millions of eye scans from Scottish optometrists to create the data set.
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, receives approval for suprachoroidal treatment for uveitic macular edema in Australia and Singapore
ARCATUS or ARVN001, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries is formally known as XIPERE in the United States and was developed by Clearside Biomedical.
FDA grants fast track designation to N-acetylcysteine amide tablets from Nacuity Pharmaceuticals
The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with retinitis pigmentosa.
HELIOS trial: Promising 1-Year results of phase I study for treating NPDR
DRSS stable/improved with OKT-TKI; drug well tolerated
Potential effect of temperature changes on anti-VEGF drugs
Home-stored anti-VEGF drugs face risks from temperature changes, pointing to a need to protect efficacy and avoid dangerous contamination.
PulseSight Therapeutics submits Clinical Trial Authorization for phase I trial of PST-611
The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy
Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT
The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics License Application in the first quarter of 2025.
Macrophomina phaseolina: An emerging ocular infection in humans
They report a case of endophthalmitis and undertook a literature review to identify previous infections with this pathogen.
Cost-effectiveness of AI pediatric eye screening
Cost among other factors may deter patients from screening, especially in rural and low-resource settings.
Inflammasome Therapeutics announces positive topline 3-month data of K8 implant in patients with GA
In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.
RhyGaze secures Series A financing of $86 million to further novel gene therapy
The funding will support activities like formal pharmacology and toxicology testing.
EyePoint Pharmaceuticals provides company updates, 2025 milestones for Duravyu
The company's lead product candidate Duravyu (vorolanib intravitreal insert), f/k/a EYP-1901, is anticipating topline data from several clinical trials in 2026.
InflammX Therapeutics enters into option agreement with Bausch + Lomb
InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration.
Positive association between the dietary inflammatory index and non-refractive visual impairment in US patients
Ashvattha Therapeutics secures $50M in financing to advance clinical trials
The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME
Samsara Vision announces positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery
The retrospective SING IMT study included 35 patients (55 years or older) with late-stage age-related macular degeneration (AMD).
Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)
Previously, Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).
4DMT releases positive topline interim data from Part 1 of the SPECTRA clinical trial
The objective of this trial was to evaluate safety and tolerability and identify dose level for further evaluation.
Bausch + Lomb acquires Whitecap Biosciences
Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.
Positive 2-year safety and efficacy update for Phase 1/2 OCU400 for the treatment of RP
OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.
City Therapeutics and Bausch + Lomb collaborate on GA treatment candidate
City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.
New research links retinal imaging and deep learning to improved schizophrenia detection
Topline results from phase 2b clinical trial of UBX1325 for DME expected in Q1 2025
This phase 2b study (ASPIRE) is currently underway.
A connection between sleep apnea and AMD
The FDA accepts revised supplemental New Drug Application for IZERVAY
The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.
Companies appoint new leadership across the industry
Several pharmaceutical companies have announced new appointments of executives and board members as they prepare for growth in 2025.
Aviceda Therapeutics completes $207.5 million Series C financing in support of AVD-104 for geographic atrophy treatment
The financing will go toward its ongoing phase 2b/3 and planned pivotal phase 3 clinical trial for AVD-104.
